Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation

Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome

Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481 · see citing works

Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen

Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758 · see citing works

Valproate Induces Replication-independent Active DNA Demethylation

Detich, N., Bovenzi, V., & Szyf, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303740200 · Cited by 345 · see citing works

Synergistic Effect of Histone Hyperacetylation and DNA Demethylation in the Reactivation of the FMR1 Gene

Chiurazzi, P., Grazia Pomponi, M., Pietrobono, R., Bakker, C. E., Neri, G., & Oostra, B. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.12.2317 · Cited by 217 · see citing works

Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia

Bug, G., Ritter, M., Waßmann, B., Schoch, C., Heinzel, T., Schwarz, K., Romanski, A., Krämer, O. H., Kampfmann, M., Hoelzer, D. F., et al. (2005) · Cancer · doi:10.1002/cncr.21589 · Cited by 184 · see citing works

The role of histone acetylation in SMN gene expression

Kernochan, L. E., Russo, M. L., Woodling, N. S., Huynh, T. N., Avila, A. M., Fischbeck, K. H., & Sumner, C. J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi130 · Cited by 164 · see citing works

The History of Valproate in Clinical Neuroscience

Henry, T. R., & Schmahl, C. G. (2015) · Psychopharmacology Bulletin · doi:10.64719/pb.7071 · Cited by 124 · see citing works

Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine

Pietrobono, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf434 · Cited by 118 · see citing works

Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments

Tabolacci, E., Pietrobono, R., Moscato, U., Oostra, B. A., Chiurazzi, P., & Neri, G. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201393 · Cited by 92 · see citing works

Histone deacetylase inhibitors decrease reelin promoter methylation in vitro

Mitchell, C. P., Chen, Y., Kundaković, M., Costa, E., & Grayson, D. R. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03040.x · Cited by 78 · see citing works

High-dose tizanidine abuse.

ZULLINO, D. F., Eskenasy, A. C., & Beeson, J. (2003) · PubMed · Cited by 31 · see citing works

Therapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder

Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404 · see citing works

The Role of Histone Acetylation in Memory Formation and Cognitive Impairments

Peixoto, L., & Abel, T. G. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.86 · Cited by 336 · see citing works

Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics

Bagni, C., Tassone, F., Neri, G., & Hagerman, R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63141 · Cited by 321 · see citing works

Síndrome de X Frágil

Saldarriaga, W., Tassone, F., González-Teshima, L. Y., Forero-Forero, J. V., Ayala‐Zapata, S., & Hagerman, R. J. (2014) · Colombia medica · doi:10.25100/cm.v45i4.1810 · Cited by 122 · see citing works

The promise and perils of HDAC inhibitors in neurodegeneration

Didonna, A., & Opal, P. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.147 · Cited by 120 · see citing works

Fragile X syndrome.

Saldarriaga, W., Tassone, F., González-Teshima, L. Y., Forero-Forero, J. V., Ayala‐Zapata, S., & Hagerman, R. J. (2014) · PubMed Central · Cited by 109 · see citing works

Histone Deacetylases Suppress CGG Repeat–Induced Neurodegeneration Via Transcriptional Silencing in Models of Fragile X Tremor Ataxia Syndrome

Todd, P. K., Oh, S. Y., Krans, A., Pandey, U. B., Prospero, N. A. D., Min, K., Taylor, J. P., & Paulson, H. L. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001240 · Cited by 99 · see citing works

Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development

Pop, A. S., Gomez‐Mancilla, B., Neri, G., Willemsen, R., & Gasparini, F. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3330-3 · Cited by 94 · see citing works

Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases

Qiu, X., Xiao, X., Li, N., & Li, Y. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.09.002 · Cited by 89 · see citing works

Epigenetic modifications in valproic acid-induced teratogenesis

Tung, E. W. Y., & Winn, L. M. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.08.001 · Cited by 85 · see citing works

Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome

Kozikowski, A. P., Shen, S., Pardo, M., Tavares, M. T., Szarics, D., Benoy, V., Zimprich, C., Kutil, Z., Zhang, G., Bařinka, C., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00600 · Cited by 80 · see citing works

Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions

Kim, K., Hessl, D. R., Randol, J. L., Espinal, G. M., Schneider, A., Protic, D. D., Aydin, E. Y., Hagerman, R. J., & Hagerman, P. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226811 · Cited by 75 · see citing works

Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys

Torrioli, M., Vernacotola, S., Setini, C., Bevilacqua, F., Martinelli, D., Snape, M., Hutchison, J. A., Di Raimo, F. R., Tabolacci, E., & Neri, G. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33484 · Cited by 71 · see citing works

Genetics and Epigenetics in Adult NeurogenesisPreprint

Hsieh, J., & Zhao, X. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018911 · Cited by 71 · see citing works

Epigenetics of Autism Spectrum Disorder: Histone Deacetylases

Tseng, C.-E. J., McDougle, C. J., Hooker, J. M., & Zürcher, N. R. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.11.021 · Cited by 71 · see citing works

Establishment of Reporter Lines for Detecting Fragile X Mental Retardation (FMR1) Gene Reactivation in Human Neural Cells

Li, M., Zhao, H., Ananiev, G. E., Musser, M. T., Ness, K. H., Maglaque, D. L., Saha, K., Bhattacharyya, A., & Zhao, X. (2016) · Stem Cells · doi:10.1002/stem.2463 · Cited by 54 · see citing works

DNA Methylation, Mechanisms of FMR1 Inactivation and Therapeutic Perspectives for Fragile X Syndrome

Nobile, V., Pucci, C., Chiurazzi, P., Neri, G., & Tabolacci, E. (2021) · Biomolecules · doi:10.3390/biom11020296 · Cited by 50 · see citing works

DNA Methylation Changes in Valproic Acid-Treated HeLa Cells as Assessed by Image Analysis, Immunofluorescence and Vibrational Microspectroscopy

Veronezi, G. M. B., Felisbino, M. B., Gatti, M. S. V., Mello, M. L. S., & Vidal, B. D. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170740 · Cited by 49 · see citing works

The FRAXopathies: Definition, overview, and update

Pirozzi, F., Tabolacci, E., & Neri, G. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.34113 · Cited by 46 · see citing works

Chromatin Remodeling, Cell Proliferation and Cell Death in Valproic Acid-Treated HeLa Cells

Felisbino, M. B., Tamashiro, W. M. D. S. C., & Mello, M. L. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029144 · Cited by 46 · see citing works

Emerging pharmacologic treatment options for fragile X syndrome

Erickson, C. A., Schaefer, T. L., & Davenport, M. H. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s35673 · Cited by 43 · see citing works

Repurposing available drugs for neurodevelopmental disorders: The fragile X experience

Tranfaglia, M. R., Thibodeaux, C., Mason, D. J., Brown, D., Roberts, I., Smith, R. J., Guilliams, T., & Cogram, P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.004 · Cited by 39 · see citing works

Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X Syndrome

Tabolacci, E., Palumbo, F., Nobile, V., & Neri, G. (2016) · Genes · doi:10.3390/genes7080049 · Cited by 37 · see citing works

Epigenetics, fragile X syndrome and transcriptional therapy

Tabolacci, E., & Chiurazzi, P. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36264 · Cited by 35 · see citing works

Genome-wide methylation analysis demonstrates that 5-aza-2-deoxycytidine treatment does not cause random DNA demethylation in fragile X syndrome cells

Tabolacci, E., Mancano, G., Lanni, S., Palumbo, F., Goracci, M., Ferrè, F., Helmer‐Citterich, M., & Neri, G. (2016) · Epigenetics & Chromatin · doi:10.1186/s13072-016-0060-x · Cited by 33 · see citing works

Human pluripotent stem cell models of Fragile X syndrome

Bhattacharyya, A., & Zhao, X. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.11.011 · Cited by 33 · see citing works

Modelling fragile X syndrome in the laboratory setting: A behavioral perspective

Melancia, F., & Trezza, V. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.04.042 · Cited by 29 · see citing works

Translational Regulation of NeuroD1 Expression by FMRP: Involvement in Glutamatergic Neuronal Differentiation of Cultured Rat Primary Neural Progenitor Cells

Jeon, S. J., Kim, J., Kim, K. C., Han, S. M., Go, H. S., Seo, J. E., Choi, C. S., Ryu, J. H., Shin, C. Y., & Song, M. (2013) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-013-0014-9 · Cited by 23 · see citing works

Pharmacological Reactivation of the Silenced FMR1 Gene as a Targeted Therapeutic Approach for Fragile X Syndrome

Kumari, D., Gazy, I., & Usdin, K. (2019) · Brain Sciences · doi:10.3390/brainsci9020039 · Cited by 21 · see citing works

Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression

Yu, D., Sakurai, F., & Corey, D. R. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.07.053 · Cited by 13 · see citing works

Epigenetic insights into Fragile X Syndrome

Xie, L., Li, H., Xiao, M., Chen, N., Zang, X., Liu, Y., Ye, H., & Tang, C. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1432444 · Cited by 7 · see citing works

Advances in Human Stem Cells and Genome Editing to Understand and Develop Treatment for Fragile X Syndrome

Zhao, X., & Bhattacharyya, A. (2020) · Advances in neurobiology · doi:10.1007/978-3-030-45493-7_2 · Cited by 3 · see citing works

Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract

Wang, Z., Yue, Y., Han, P., Sa, R., Ren, X., Wang, J., Bai, H., & Yu, H. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.05.001 · Cited by 3 · see citing works

Histone Deacetylase Inhibitors: A Novel Therapeutic Approach for Cognitive Disorders

Labrie, V. (2011) · Springer eBooks · doi:10.1007/978-3-642-17426-1_12 · Cited by 2 · see citing works

The Role of Oxidative Stress and Epigenetic Modifications in Valproic Acid-Induced Teratogenesis in the Mouse

Tung, E. W. Y. (2012) · QSpace (Queen's University Library) · Cited by 2 · see citing works

Epigenetic causes of intellectual disability—the fragile X syndrome paradigm

Tabolacci, E., & Neri, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800226-1.00006-x · Cited by 1 · see citing works

Epigenetic causes of intellectual disability—the fragile X syndrome paradigm

Tabolacci, E., & Neri, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18516-8.00007-7 · Cited by 1 · see citing works

Remodelação cromatínica, anomalias cromossômicas e morte celular em condições de inibição de deacetilases de histonas em células HeLa e 3T3

Felisbino, M. B. (2012) · doi:10.47749/t/unicamp.2012.871361 · Cited by 1 · see citing works

Response to “Valproic Acid and ADHD Symptoms in Fragile X Syndrome: More Evidence Is Needed”

Snape, M., & Neri, G. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33606

What Mechanisms Induce Methylation of FMR1 Gene Full Mutation? A Still Unanswered Question

Tabolacci, E., & Neri, G. (2016) · Epigenetics and human health · doi:10.1007/978-3-319-27186-6_8

Reactivation of the FMR1 Gene

Tabolacci, E., & Chiurazzi, P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00017-2

Vignettes: Models in Absentia

Denman, R. B. (2011) · Results and problems in cell differentiation · doi:10.1007/978-3-642-21649-7_19

Efeitos do ácido valproico sobre a metilação do DNA durante o ciclo celular de células HeLa

Rocha, M. A. (2018) · doi:10.47749/t/unicamp.2018.1092236

Ação do ácido valproico e da tricostatina A na organização cromatínica e sua regulação por fatores epigenéticos em células HepG2 sob condições de hiperglicemia

Felisbino, M. B. (2016) · doi:10.47749/t/unicamp.2016.976565

Synergistic Effect of Histone Hyperacetylation and DNA Demethylation in the Reactivation of the FMR1 Gene

Chiurazzi, P., Grazia Pomponi, M., Pietrobono, R., Bakker, C. E., Neri, G., & Oostra, B. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.12.2317 · Cited by 217 · see citing works

Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments

Tabolacci, E., Pietrobono, R., Moscato, U., Oostra, B. A., Chiurazzi, P., & Neri, G. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201393 · Cited by 92 · see citing works

Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys

Torrioli, M., Vernacotola, S., Setini, C., Bevilacqua, F., Martinelli, D., Snape, M., Hutchison, J. A., Di Raimo, F. R., Tabolacci, E., & Neri, G. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33484 · Cited by 71 · see citing works

Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X Syndrome

Tabolacci, E., Palumbo, F., Nobile, V., & Neri, G. (2016) · Genes · doi:10.3390/genes7080049 · Cited by 37 · see citing works

Genome-wide methylation analysis demonstrates that 5-aza-2-deoxycytidine treatment does not cause random DNA demethylation in fragile X syndrome cells

Tabolacci, E., Mancano, G., Lanni, S., Palumbo, F., Goracci, M., Ferrè, F., Helmer‐Citterich, M., & Neri, G. (2016) · Epigenetics & Chromatin · doi:10.1186/s13072-016-0060-x · Cited by 33 · see citing works